Close
Platforms
Online Inquiry

CONTACT US

USA:

UK:
Call us at:
USA:
UK:
Fax:
Email:

Tetravalent Bispecific (TetraBi) T-cell Engager Platform

Early clinical results and the new improvements to T-cell engager design has spurred the discovery and clinical advance of 66 bispecific T-cell engagers as of January 7, 2020. Creative Biolabs has organized a staff of outstanding scientists who are committed to bispecific T-cell engager research and project development for many years. Tetravalent bispecific (TetraBi) T-cell engager, which is one antibody-based molecule but targets tumor cell and T-cell simultaneously, is a novel option for cancer therapy. By applying our staff’s experience and a proven technology system, we provide highly customized solutions to meet your basic, applied, and clinical research demands in the development of TetraBi antibody.

Tetravalent Bispecific (TetraBi) T-cell Engager Platform

Novel TetraBi Antibodies: an Option for Cancer Therapy

T-cells, the most powerful agents of the immune system, play an important role in killing tumor cells. Engaging T-cells with tumor cells using bispecific antibodies (BsAbs) is an attractive strategy to harness T-cells for treating cancers. Bispecific antibodies (BsAbs) are designed to combine tumor-associated antigen binding specificity and T-cell binding potential into one molecule. The key advantage of bispecific-based T-cell engagers is the engagement of these professional killers against tumors with the potential to combine with immune checkpoint modulators. However, in the early clinical development of T-cell engagers, many of the first-generation bispecific antibodies have exhibited lackluster safety, efficacy, and manufacturability profiles. Although this resistance could be partially reversed by anti-immune checkpoint treatment, targeting two pathways through one antibody-based molecule may provide a strategic advantage over the combination of BsAbs and checkpoint inhibitors. It is exciting is that TetraBi antibodies offer a feasible option for cancer therapy.

TetraBi T-cell Engager Development Service at Creative Biolabs

With years of experience in the design of T-cell engagers for tumors, scientists at Creative Biolabs have gained a comprehensive perspective on the variables that can impact T-cell engagement. They include the antibody format, membrane proximity of the epitope bound on the tumor antigen, epitopes bound on CD3, target binding affinity, half-life, etc. When considering the interdependencies of the structure and function of T-cell engagers, it is important to highlight the antibody format used and its impact on developability.

Tetravalent Bispecific (TetraBi) T-cell Engager Platform

Creative Biolabs has perfected our technical pipelines in the development of TetraBi antibodies with IgG-scFv or dual-variable-domain immunoglobulin G (DVD-IgG) format using in-house technologies. Diverse tumor antigens, including lymphocyte restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123, could be targeted for TetraBi T-cell engager development. We are pleased to tailor the most appropriate strategies to meet every unique need of our clients. This novel TetraBi T-cell engager technology can promote the selective reactivation of anti-tumor T-cells, and potentially, may offer a feasible option for cancer therapy.

Highlights of Our TetraBi Antibodies

  • Lower immunogenicity but with stronger binding affinity
  • Long circulating half-lives
  • Higher safety through monovalent binding to CD3
  • Fc engineering for better control of immune effector function

The development process at Creative Biolabs is the fastest and most streamlined system to get your TetraBi antibody development project fully completed. Trust Creative Biolabs to develop a solution that will provide the satisfactory TetraBi antibody you require. For more detailed information, please feel free to contact us or directly send us an inquiry.

References

  1. Hou, W.; et al. A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer. Investigational new drugs. 2019 Oct 1;37(5): 876-89.
  2. Hoseini, S.S.; et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood advances. 2018, 2(11): 1250-8.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

Key Updates

Receive our latest news and insights.